{"id":683963,"date":"2022-09-12T08:03:46","date_gmt":"2022-09-12T12:03:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/"},"modified":"2022-09-12T08:03:46","modified_gmt":"2022-09-12T12:03:46","slug":"quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/","title":{"rendered":"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Quince Therapeutics Presents Preclinical Data at ASBMR 2022 <\/b><b>Demonstrating Application of Bone-targeting Platform for <\/b><b>Spinal Fusion and Bone Cancer Indications<\/b><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nQuince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company\u2019s participation at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asbmr.org%2Fannual-meeting&amp;esheet=52882423&amp;newsitemid=20220912005365&amp;lan=en-US&amp;anchor=The+American+Society+for+Bone+and+Mineral+Research+Annual+Meeting&amp;index=1&amp;md5=d916da5d6ee392756d06cf9135a30307\">The American Society for Bone and Mineral Research Annual Meeting<\/a> (ASBMR 2022), which took place September 9 to September 12, 2022,<b \/>in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the company\u2019s highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications.\n<\/p>\n<p>\nStewart Low, Quince\u2019s head of discovery, said, \u201cSupported by more than 10 years of extensive preclinical studies, we believe Quince\u2019s proprietary bone-targeting platform can be harnessed to enable the precise delivery of drug concentrated directly to the site of bone injury and disease to accelerate healing. We are excited to continue to bring our preclinical research forward to demonstrate the potential of our proprietary targeting platform with additional indications in spinal fusion and bone cancer as we seek to improve outcomes in underserved patient populations.\u201d\n<\/p>\n<p><b>ASBMR 2022 Poster Highlights<\/b><\/p>\n<p>\nThe following are highlights from the company\u2019s poster presentations of preclinical data exploring spinal fusion and bone cancer indications at ASBMR 2022:\n<\/p>\n<p><i>Poster: Improved Spinal Fusion Through Targeted Delivery of Abaloparatide<\/i><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nWith more than 400,000 spinal fusions performed in the U.S. every year, Quince believes there is an opportunity to utilize its bone-targeting platform to improve patient outcomes in spinal fusion with its NOV004 targeted therapeutic.\n<\/li>\n<li>\nQuince developed a bone-targeting compound based on acidic oligopeptides which is designed to stimulate bone growth at spinal fusion sites.\n<\/li>\n<li>\nIn preclinical studies, NOV004 concentrated at spinal fusion sites to demonstrate accelerated repair in treated animals which resulted in significantly improved blinded radiographic fusion scores compared to animals treated with the current standard of care, bone morphogenic protein-2 (BMP-2).\n<\/li>\n<li>\nIn addition, NOV004\u2019s subcutaneous administration would allow for repeat dosing post operatively compared to current spinal fusion strategies that generally require surgery to apply the drug and only allow for one application.\n<\/li>\n<\/ul>\n<p><i>Poster: Evaluating the Efficacy of an Acidic Oligopeptide-radioisotope Chelator Conjugate to Target and Deliver Radioactive Agents to Bone Cancers<\/i><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nWith five-year survival rates of less than 20% to 30% in patients with breast and prostate cancer related bone metastases, Quince believes there is an opportunity to utilize its bone-targeting platform to develop targeted radiotherapeutics to improve patient outcomes in breast and bone cancer related bone tumor growth.\n<\/li>\n<li>\nQuince developed a radioactive acidic oligopeptide conjugate to target and deliver imaging and therapeutic agents with high tumor-bearing bone specificity.\n<\/li>\n<li>\nIn preclinical studies, the company confirmed that its targeting moiety can localize to metastatic tumor sites in both osteolytic and osteoblastic lesions and can selectively deliver both fluorescent dye and radioisotope-chelated agents without obvious offsite localization.\n<\/li>\n<li>\nIn addition to demonstrating rapid renal excretion, the radioactive conjugates were retained in the diseased bone even at two weeks post injection.\n<\/li>\n<\/ul>\n<p>\nTo view the posters presented at ASBMR 2022, please visit the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fquincetx.com%2Fscience%2F&amp;esheet=52882423&amp;newsitemid=20220912005365&amp;lan=en-US&amp;anchor=Science&amp;index=2&amp;md5=2ac084a334aa32677f811add38f9d019\">Science<\/a> section of Quince\u2019s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fquincetx.com%2F&amp;esheet=52882423&amp;newsitemid=20220912005365&amp;lan=en-US&amp;anchor=corporate+website&amp;index=3&amp;md5=53418eafc35318776982ec2303ff9523\">corporate website<\/a>.\n<\/p>\n<p><b>About Quince Therapeutics<\/b><\/p>\n<p>\nQuince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince\u2019s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company\u2019s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.quincetx.com&amp;esheet=52882423&amp;newsitemid=20220912005365&amp;lan=en-US&amp;anchor=www.quincetx.com&amp;index=4&amp;md5=dda0098dd4a066eb8c43a4a0e9c2f116\">www.quincetx.com<\/a> and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.\n<\/p>\n<p><b>Forward-looking Statements<\/b><\/p>\n<p>\nStatements in this news release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201ccan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201cencouraged,\u201d \u201cpositioned,\u201d or other similar words. Examples of forward-looking statements include, among others, the clinical development and strategic development path for NOV004; the timing and success of the company\u2019s clinical trials and related data, including plans and the ability to initiate, conduct and\/or complete the Phase 1 clinical studies for NOV004; the potential therapeutic benefits, safety, and efficacy of the company\u2019s bone-targeting platform, product candidate and discovery pipeline. Forward-looking statements are based on Quince Therapeutic\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled \u201cRisk Factors\u201d in the company\u2019s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on August 9, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20220912005365\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20220912005365\/en\/<\/a><\/span><\/p>\n<p><b>Quince Therapeutics Contact:<br \/>\n<\/b><br \/>Stacy Roughan<br \/>\n<br \/>Quince Therapeutics, Inc.<br \/>\n<br \/>Vice President, Corporate Communications &amp; Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@quincetx.com\">ir@quincetx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Pharmaceutical Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220912005365\/en\/1528430\/3\/Quince_Therapeutics_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company\u2019s participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022,in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the company\u2019s highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications. Stewart Low, Quince\u2019s head of discovery, said, \u201cSupported &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-683963","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company\u2019s participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022,in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the company\u2019s highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications. Stewart Low, Quince\u2019s head of discovery, said, \u201cSupported &hellip; Continue reading &quot;Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-12T12:03:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications\",\"datePublished\":\"2022-09-12T12:03:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/\"},\"wordCount\":1020,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/\",\"name\":\"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2022-09-12T12:03:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/","og_locale":"en_US","og_type":"article","og_title":"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications - Market Newsdesk","og_description":"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company\u2019s participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022,in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the company\u2019s highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications. Stewart Low, Quince\u2019s head of discovery, said, \u201cSupported &hellip; Continue reading \"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-12T12:03:46+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications","datePublished":"2022-09-12T12:03:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/"},"wordCount":1020,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/","name":"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2022-09-12T12:03:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220912005365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quince-therapeutics-presents-preclinical-data-at-asbmr-2022-demonstrating-application-of-bone-targeting-platform-for-spinal-fusion-and-bone-cancer-indications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/683963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=683963"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/683963\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=683963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=683963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=683963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}